ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2306

Demographic and Clinical Characteristics of Hispanic Children with Juvenile Idiopathic Arthritis: An International, Multicenter Cross-Sectional Study

Martha Rodriguez1, Melissa Tesher1, Deirdre De Ranieri1, Linda Wagner-Weiner2, Tamar Rubinstein3, Janet Orrock4, Christine Arango5, Angela Mosquera5, Carmen Tineo6, Romilda Salas7, Esthela Loyo8, Karen Onel9 and Maria Alkureishi10, 1Pediatric Rheumatology, The University of Chicago Medicine, Chicago, IL, 2The University of Chicago Medicine, Chicago, IL, 3Albert Einstein College of Medicine, Children's Hospital at Montefiore, New York, NY, 4Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, NY, Albania, 5Pediatric Rheumatology, Pediatric rheumatology post graduate program El Bosque University, Bogota, Colombia, 6Division of Rheumatology, Hospital Regional Universitario José Ma Cabral Baez, Santiego, Dominican Republic, 7Rheumatology, Hospital Regional Universitario José Ma Cabral Baez, Santiago, Dominican Republic, 8Departamento de Reumatologia, Hospital Regional Universitario José Ma Cabral Baez, Santiago, Dominican Republic, 9Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, 10Pediatrics, The University of Chicago Medicine, Chicago, IL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Juvenile Arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Higher disease activity has been described in Hispanic patients with Juvenile Idiopathic Arthritis (JIA) living in the United States (US) vs non-Hispanics. There is no data available comparing JIA disease activity among Hispanics living in the US vs Latin America, or between Hispanic subgroups. We aim to describe the clinical characteristics of Hispanic children with JIA at several centers in the United States and in Latin America.

Methods: We analyzed preliminary data of 95 subjects from 4 centers (US: 2, Latin America:2) with a confirmed diagnosis of JIA based on the revised ILAR criteria with age of disease onset ≤16 years old. Subjects were grouped based on self-reported ethnicity and residency, with 52 Hispanics residing in Latin America (Colombia and Puerto Rico). In the US, 20 Hispanics and 23 non- Hispanic subjects were surveyed. Data collection is ongoing; we anticipate 240 subjects by completion of the study. We compared clinical characteristics, physician assessment of disease activity, parent/subject assessment of disease activity and pain, CHAQ score and presence/absence of imaging evidence of joint damage among the three groups.

Results: There was a significant difference in distribution of JIA subtypes between groups. Oligoarticular JIA was the most common among non-Hispanic US patients (27%) and polyarticular RF negative was the most common subtype in both Hispanic groups (35%). RF positive polyarticular JIA was more common in US Hispanics (25%) vs US non-Hispanics (13%), but lower in Hispanics residing in Latin America (12%). HLA B27 positivity was more frequent in US non-Hispanics (18% vs 5% in Hispanics in US and 15% in Hispanics in Latin America). Radiographic damage was significant more frequent among Latin American Hispanics (42%), compared to US Hispanics (35%) and US non-Hispanics (22%). Systemic steroid use was more frequent among Latin American Hispanics. Treatment with biologics was highest in US Hispanics (80%) vs US Non-Hispanics (70%); 54% of subjects in Latin America reported receiving biologics. Non-biologic DMARD use was similarly prevalent in the three groups: 90% in Latin American patients, 86% in US non-Hispanics, and 85% in US Hispanics. CHAQ scores were slightly higher in non-Hispanics; however physician global disease assessment was worse in Hispanics, particularly those residing in US.

Conclusion: Radiographic changes were significantly higher in all Hispanics which may reflect more aggressive disease as well as decreased use of biologic medications in Latin America. Systemic steroids are used more commonly among Latin American patients which likely reflects decreased availability of other medications, particularly biologics. In addition to treatment variation, genetics and environmental factors may contribute to the variable phenotypic expression of JIA found among Hispanic groups in this preliminary study. An improved understanding of the characteristics of JIA among Hispanic children is essential to guide disease management and better meet the needs of this population.


Disclosure: M. Rodriguez, None; M. Tesher, None; D. De Ranieri, None; L. Wagner-Weiner, None; T. Rubinstein, None; J. Orrock, None; C. Arango, None; A. Mosquera, None; C. Tineo, None; R. Salas, None; E. Loyo, None; K. Onel, None; M. Alkureishi, None.

To cite this abstract in AMA style:

Rodriguez M, Tesher M, De Ranieri D, Wagner-Weiner L, Rubinstein T, Orrock J, Arango C, Mosquera A, Tineo C, Salas R, Loyo E, Onel K, Alkureishi M. Demographic and Clinical Characteristics of Hispanic Children with Juvenile Idiopathic Arthritis: An International, Multicenter Cross-Sectional Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/demographic-and-clinical-characteristics-of-hispanic-children-with-juvenile-idiopathic-arthritis-an-international-multicenter-cross-sectional-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/demographic-and-clinical-characteristics-of-hispanic-children-with-juvenile-idiopathic-arthritis-an-international-multicenter-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology